ライフサイエンスコーパス: Behcet's disease

1 or the treatment of ocular manifestations of Behcet's disease.

2 enic pathways in the spondyloarthritides and Behcet's disease.

3 on in the management of venous thrombosis in Behcet's disease.

4 fied 5 novel genetic susceptibility loci for Behcet's disease.

5 ve emerged as a successful approach to treat Behcet's disease.

6 venile idiopathic arthritis, sarcoidosis and Behcet's disease.

7 d the International Study Group criteria for Behcet's disease.

8 ss in patients with a familial occurrence of Behcet's disease.

9 her characteristic or diagnostic features of Behcet's disease.

10 95% confidence interval [CI], 0.19-0.74) and Behcet's disease (aHR, 0.10; 95% CI, 0.01-0.85) were ass

11 genotypes in 1,209 Turkish individuals with Behcet's disease and 1,278 controls.

12 a number of inflammatory diseases, including Behcet's disease and age-related macular degeneration.

13 lvement of other autoimmune diseases such as behcet's disease and ankylosing spondylitis, and ocular

14 the genetic association between HLA-B*51 and Behcet's disease and exploring additional susceptibility

15 cause monogenic recessive diseases: MEFV in Behcet's disease and Henoch-Schonlein purpura, and A1AT

16 (GWAS) in vasculitis have been published, in Behcet's disease and Kawasaki disease; none of the genes

17 as demonstrated efficacy in the treatment of Behcet's disease and other forms of posterior uveitis.

18 udy is the first systematic genome screen in Behcet's disease and provides evidence of linkage to sev

19 ious uveitides (the ocular manifestations of Behcet's disease and sarcoidosis) based on multicolor fl

20 mal set of 5 markers that accurately predict Behcet's disease and sarcoidosis.

21 The genetic association between Behcet's disease and UBAC2 was established, replicated,

22 and mortality of large vessel vasculitis in Behcet's disease are improving.

23 lear cells of individuals homozygous for the Behcet's disease-associated "G" allele.

24 nfliximab and interferon alpha, particularly Behcet's disease-associated uveitis.

25 chemokines and its receptor in patients with Behcet's disease (BD) and their associations with diseas

26 ssociated with the autoinflammatory disorder Behcet's disease (BD) in epistasis with HLA-B*51, which

27 ly genes with Vogt-Koyanagi-Harada (VKH) and Behcet's disease (BD) in Han Chinese.

28 matosus (SLE) in subjects from Colombia; and Behcet's disease (BD) in subjects from Turkey.

29 Behcet's disease (BD) is a multi-system inflammatory dis

30 Behcet's disease (BD) is a multisystem disease of unknow

31 Behcet's disease (BD) is a multisystem disorder of unkno

32 Behcet's disease (BD) is a multisystem immune-mediated i

33 Behcet's disease (BD) is a multisystem relapsing inflamm

34 Behcet's disease (BD) is a rare, multisystem inflammator

35 Behcet's disease (BD) is reportedly associated with poly

36 nous retinal detachment (RD) associated with Behcet's disease (BD).

37 aging features of myelopathy associated with Behcet's disease (BD).

38 lpha) may play a role in the pathogenesis of Behcet's disease (BD).

39 r uveitis cases included diagnosis with JIA, Behcet's disease, bilateral uveitis, history of cataract

40 We analyzed 1,900 Turkish Behcet's disease cases and 1,779 controls genotyped with

41 with 311,459 SNPs in 1,215 individuals with Behcet's disease (cases) and 1,278 healthy controls from

42 analysis of 24,834 variants in 2 independent Behcet's disease cohorts from 2 ancestry groups.

43 correlated with disease activity in terms of Behcet's Disease Current Activity Form (BDCAF) (p < 0.00

44 und in the peripheral blood of patients with Behcet's disease during episodes of ocular inflammation.

45 between an HLA class I antigen, HLA-B51, and Behcet's disease has long been known.

46 anding knowledge on large vessel problems in Behcet's disease, highlighting recent contributions.

47 Ocular involvement in Behcet's disease, if untreated, leads to blindness.

48 patients, pars planitis in 16 patients, and Behcet's disease in 13 patients.

49 ed the genetic association between UBAC2 and Behcet's disease in 3 independent sets of patients and c

50 ntification of other susceptibility loci for Behcet's disease in multicase families.

51 etic effects that increase susceptibility to Behcet's disease in the UBAC2 locus.

52 Most published diagnostic criteria for Behcet's disease include the classic triad of orogenital

53 Behcet's disease is a genetically complex disease of unk

54 Behcet's disease is a multisystem inflammatory disorder

55 Behcet's disease is an inflammatory disease characterize

56 The vasculopathy of Behcet's disease is distinctive among the vasculitides i

57 gest that the robust HLA-B*51 association in Behcet's disease is explained by a variant located betwe

58 Behcet's disease is generally considered to be a multifa

59 teristics of ocular disease in children with Behcet's disease is presented.

60 An article on the course of Behcet's disease is reviewed as well as another article

61 sic part of familial Mediterranean fever and Behcet's disease management.

62 ared to ankylosing spondylitis (p = 0.0001), behcet's disease (p = 0.0001), presumed latent tuberculo

63 pect to ankylosing spondylitis (p = 0.0001), behcet's disease, (p = 0.0001) presumed latent tuberculo

64 We studied a total of 676 Behcet's disease patients and 1,096 controls.

65 olving patients with ankylosing spondylitis, behcet's disease, presumed sarcoidosis, presumed latent

66 Behcet's disease runs a chronic course, with unpredictab

67 Individuals with Behcet's disease suffer from episodic inflammation often

68 irst step toward the identification of novel Behcet's disease susceptibility genes.

69 ate immune response to microbial exposure in Behcet's disease susceptibility.

70 a patient who had a vasculopathy fitting the Behcet's disease type, but who lacked the other characte

71 Behcet's disease typically arises in young adults, altho

72 To discover new susceptibility loci for Behcet's disease, we performed a genome-wide association

73 The disorder resembles Behcet's disease, which is typically considered a polyge

74 ulitis occurs in a subgroup of patients with Behcet's disease who are at high risk for disease-relate

75 We confirmed the known association of Behcet's disease with HLA-B*51 and identified a second,

76 ave shown an increased rate of thrombosis in Behcet's disease, with a different clinical presentation